Fat loss.
The peptide landscape for fat loss has exploded since GLP-1 agonists went mainstream. From FDA-approved options like Semaglutide and Tirzepatide to research compounds like Retatrutide and AOD-9604, there are now multiple evidence-backed pathways to accelerate fat loss.
The Fat Loss stack.
A balanced protocol engineered for fat loss via targeted peptide synergy.
6 peptides, precisely sequenced.
Each peptide plays a specific role. Removing any one breaks the synergy.
Semaglutide
GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection.
Tirzepatide
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Retatrutide
Multi-receptor activation for appetite suppression, fat oxidation, energy expenditure. Unique triple agonism at GLP-1, GIP, and glucagon receptors delivers synergistic metabolic ef
AOD-9604
Mimics GH fat-burning domain. Stimulates lipolysis and inhibits lipogenesis by acting on beta-3 adrenergic receptors in fat tissue, without binding to the GH receptor.
Tesamorelin
Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
MOTS-c
Regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline.
Customize this protocol
Open this protocol in the Cycle Planner to adjust duration, swap peptides, and generate your reference dosing chart.
Based on published trial data.
Frequently asked questions.
What's the best peptide for fat loss?
Based on clinical trial data, Tirzepatide (dual GLP-1/GIP agonist) shows the strongest results at ~22% body weight reduction in the SURMOUNT trials. Semaglutide is the most widely prescribed at ~15% reduction. For research-only options, AOD-9604 targets fat-specific lipolysis and MOTS-c enhances metabolic function. → Read more at peptidex.app/best/fat-loss
What's the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist (single target), while tirzepatide is a dual GLP-1/GIP agonist. Tirzepatide generally produces greater weight loss (~22% vs ~15%) in clinical trials due to the additive metabolic effects of GIP receptor activation. Both are FDA-approved. → Read more at peptidex.app/compare/semaglutide-vs-tirzepatide
Do peptides require a prescription?
Only FDA-approved peptides require a prescription: Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), Tesamorelin (Egrifta), and PT-141 (Vyleesi). All other peptides indexed on PeptiDex are research-only compounds sold for laboratory use. → Read more at peptidex.app/faq
How long does it take for peptides to work?
Results vary by peptide. GLP-1 agonists (Semaglutide) show appetite effects within days and measurable weight loss by week 4-8. BPC-157 may show healing improvements within 1-2 weeks. GH secretagogues (CJC-1295/Ipamorelin) typically require 4-8 weeks for noticeable body composition changes. → Read more at peptidex.app/library
What is Retatrutide?
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed ~24% body weight reduction at 48 weeks — the highest of any anti-obesity peptide in clinical development. Not yet FDA-approved; Phase 3 trials are ongoing. → Read more at peptidex.app/library/retatrutide
§ About the Author
Dr. E. Vance
Editorial Director, PeptiDex
Dr. E. Vance is the Editorial Director at PeptiDex and leads the platform's editorial division, ensuring that every published research summary meets rigorous preclinical citation standards. With a Ph.D. in Molecular Pharmacology from Columbia Univers...
View Full Profile